AbbVie (ABBV) announced Thursday morning that its Phase 2b study of upadacitinib met the primary endpoint and all skin and itch-specific secondary endpoints.
AbbVie climbed throughout the first half of Thursday's session, before settling into a range. The stock closed up by 4.73 at $81.78 with volume at nearly a 10-month high. AbbVie has been climbing for over 2 weeks and surged to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.